Invesco Ltd. Sells 456,008 Shares of Haemonetics Co. (NYSE:HAE)

Invesco Ltd. cut its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 82.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 95,991 shares of the medical instruments supplier's stock after selling 456,008 shares during the period. Invesco Ltd. owned 0.19% of Haemonetics worth $7,495,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Whittier Trust Co. bought a new position in Haemonetics in the 4th quarter worth approximately $62,000. Parkside Financial Bank & Trust lifted its stake in shares of Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after acquiring an additional 240 shares during the period. AlphaQuest LLC boosted its holdings in Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after acquiring an additional 1,826 shares during the last quarter. KBC Group NV raised its holdings in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after purchasing an additional 712 shares during the last quarter. Finally, HighTower Advisors LLC lifted its position in Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after purchasing an additional 244 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HAE. Needham & Company LLC lowered their price target on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. JMP Securities reduced their price target on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Finally, Barrington Research reduced their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $101.22.

Haemonetics Trading Down 1.4 %

Shares of Haemonetics stock traded down $0.92 during trading hours on Wednesday, hitting $63.05. The company's stock had a trading volume of 552,251 shares, compared to its average volume of 689,703. Haemonetics Co. has a 12 month low of $55.30 and a 12 month high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a market capitalization of $3.17 billion, a PE ratio of 24.82, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. The stock has a 50 day moving average of $62.82 and a 200 day moving average of $71.91.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.